Cross-talk of membrane lipids and Alzheimer-related proteins

Jochen Walter1, Gerhild van Echten-Deckert

  • 1Department of Neurology, University of Bonn, Sigmund-Freud-Str, 25, 53127, Bonn, Germany. Jochen.Walter@ukb.uni-bonn.de.

Insights

Alzheimer's disease (AD) involves amyloid plaques and tau tangles. This review explores how cellular lipid metabolism, including cholesterol and sphingolipids, impacts AD protein interactions and disease progression.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Cell Biology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid plaques and neurofibrillary tangles.
  • Familial early-onset AD mutations implicate amyloid precursor protein (APP) and presenilins in amyloid-beta (Aβ) generation.
  • The amyloid hypothesis posits Aβ accumulation as the primary AD event.

Purpose of the Study:

  • To review the intricate relationship between cellular lipid metabolism and AD-associated proteins.
  • To discuss potential mechanisms linking lipid metabolism to AD initiation and progression.

Main Methods:

  • Review of existing literature on AD pathogenesis, protein interactions, and lipid metabolism.
  • Analysis of studies investigating the role of membrane lipids in Aβ generation and aggregation.
  • Examination of reciprocal interactions between AD proteins and lipid metabolic pathways.

Main Results:

  • Membrane lipids, including cholesterol and sphingolipids, influence Aβ generation and aggregation.
  • APP and secretases (β- and γ-secretases) interact with and affect lipid metabolic pathways.
  • AD proteins are integral membrane proteins, suggesting a crucial role for membrane lipids.

Conclusions:

  • Cellular lipid metabolism is closely linked to AD-associated proteins.
  • Lipid-protein interactions represent a significant area for understanding AD pathogenesis.
  • Targeting lipid metabolism may offer novel therapeutic strategies for Alzheimer's disease.

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
10.4K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K